Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
AUPH

Aurinia Pharmaceuticals

$6.38

-0.44 (-6.45%)

08:11
09/13/17
09/13
08:11
09/13/17
08:11
Downgrade
Aurinia Pharmaceuticals rating change at Canaccord »

Aurinia Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

Over a month ago
AUPH

Aurinia Pharmaceuticals

$5.71

-0.24 (-4.03%)

16:32
08/10/17
08/10
16:32
08/10/17
16:32
Earnings
Aurinia Pharmaceuticals reports Q2 EPS (3c) with items, consensus (12c) »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a quarter ago
AUPH

Aurinia Pharmaceuticals

$5.94

-0.03 (-0.50%)

08:15
06/16/17
06/16
08:15
06/16/17
08:15
Technical Analysis
Technical View: Aurinia Pharmaceuticals trades higher in pre-market »

The shares were last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUPH

Aurinia Pharmaceuticals

$5.94

-0.03 (-0.50%)

08:03
06/16/17
06/16
08:03
06/16/17
08:03
Hot Stocks
Aurinia Pharmaceuticals presents voclosporin remission data at EULAR »

Aurinia Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUPH

Aurinia Pharmaceuticals

$6.46

0.21 (3.36%)

08:07
06/05/17
06/05
08:07
06/05/17
08:07
Hot Stocks
Aurinia Pharma's Phase Iib Aura-Lv study demonstrates stable renal function »

Aurinia Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jun

AUPH

Aurinia Pharmaceuticals

16:03
05/17/17
05/17
16:03
05/17/17
16:03
Hot Stocks
Aurinia Pharmaceuticals doses first patient in Phase 3 voclosporin trial »

Aurinia Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUPH

Aurinia Pharmaceuticals

$7.68

0.15 (1.99%)

13:05
05/15/17
05/15
13:05
05/15/17
13:05
Options
Aurinia Pharmaceuticals call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUPH

Aurinia Pharmaceuticals

$7.68

0.15 (1.99%)

08:15
05/15/17
05/15
08:15
05/15/17
08:15
Earnings
Aurinia Pharmaceuticals reports Q1 EPS (20c) ex-items, consensus (12c) »

For the first quarter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVLN

Novelion Therapeutics

$9.93

-0.27 (-2.65%)

, APTO

Aptose Biosciences

$0.90

0.0302 (3.47%)

04:55
05/02/17
05/02
04:55
05/02/17
04:55
Conference/Events
Bloom, Burton & Co. hold a conference »

Healthcare Investor…

NVLN

Novelion Therapeutics

$9.93

-0.27 (-2.65%)

APTO

Aptose Biosciences

$0.90

0.0302 (3.47%)

AQXP

Aquinox

$14.75

0.07 (0.48%)

AUPH

Aurinia Pharmaceuticals

$7.38

0.37 (5.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 08

    May

  • 11

    May

NVLN

Novelion Therapeutics

$10.20

0.04 (0.39%)

, APTO

Aptose Biosciences

$0.87

-0.0002 (-0.02%)

07:49
05/01/17
05/01
07:49
05/01/17
07:49
Conference/Events
Bloom, Burton & Co. hold a conference »

Healthcare Investor…

NVLN

Novelion Therapeutics

$10.20

0.04 (0.39%)

APTO

Aptose Biosciences

$0.87

-0.0002 (-0.02%)

AQXP

Aquinox

$14.68

-0.04 (-0.27%)

AUPH

Aurinia Pharmaceuticals

$7.01

-0.09 (-1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 08

    May

  • 11

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.